Systemic enzyme therapy for postoperative inflammation and wound healing after orthopedic surgery: a randomized, placebo and active controlled clinical study.

ABSTRACT: This randomized, double-blind, placebo- and active-controlled clinical trial evaluated the efficacy and safety of EnMax tablets in managing postoperative inflammation and supporting wound healing following orthopedic surgery. A total of 105 patients were randomized to receive EnMax, a comparator enzyme formulation (trypsin-bromelain-rutoside), or placebo alongside standard care for 7 days. Baseline characteristics were statistically comparable across all groups. EnMax demonstrated significant clinical benefits, including substantial reductions in pain (93.10%), inflammation (89.77%), and key inflammatory biomarkers-C-reactive protein (CRP, 57% reduction) and erythrocyte sedimentation rate (ESR, 61.32% reduction) by the final visit. EnMax also outperformed both placebo and the comparator in

SUBMITTER: Suryawanshi A 

PROVIDER: S-EPMC12491591 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature